Epsiode 37 - What’s New Doc? End of the Year Updates on CAR T-cell Therapy in Multiple Myeloma

What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.